首页> 外文OA文献 >Development of novel extraction and separation methods for the determination of anthracyclines and taxanes simultaneously from biological matrices
【2h】

Development of novel extraction and separation methods for the determination of anthracyclines and taxanes simultaneously from biological matrices

机译:开发新的萃取分离方法同时测定生物基质中的蒽环类和紫杉烷

摘要

For certain types of advanced cancers patients may be given a combination of an anthracycline and a taxane for chemotherapy treatment. Despite the fact that a mixture of anthracyclines and taxanes may be administered simultaneously to patients and that accurate measurement of drug levels during chemotherapy is proven to be more beneficial to patients, currently no chromatographic method exists for the measurement of any anthracycline and taxane drugs in a single assay. It would be useful to carry out therapeutic drug monitoring (TDM) in order to assess how the patient is metabolising the drugs and to see whether the dosage is working or should be altered. Such information during therapy can be a very important clinical tool for the oncologist, enabling them to change dosage or even drug regimen on an individual basis for patients, improving outcome in the long run.udThis thesis describes the development of two different analytical methods capable of quantifying both drug types in a single assay. The first method employed the use of on-line SPE-LC-UV and this method was then transferred to a mass spectrometric detector for more sensitive monitoring of the drugs. The on-line SPE-LC-MS assay did result in lower limits of detection and was fully automated. The entire method of extraction, separation and detection was achieved on-line by column-switching between an SPE column and an analytical column. The optimum type of switching valve, extraction conditions and separating conditions were evaluated for both methods in order to obtain the highest recovery possible for each target analyte in human serum. Recoveries ranged from 86 to 117% for each analyte in the LC-UV method and from 95 to 113% for most analytes in the LC-MS assay. This research could potentially lead to the introduction of therapeutic drug monitoring in Ireland for cancer patients being treated with anthracyclines or taxanes or both.ud
机译:对于某些类型的晚期癌症,可以给患者联合使用蒽环类药物和紫杉烷类药物进行化疗。尽管可以同时对患者使用蒽环类药物和紫杉烷类药物的混合物,并且事实证明在化疗期间准确测量药物水平对患者更有益,但目前尚无色谱法可用于测量患者体内的任何蒽环类药物和紫杉烷类药物。单一测定。进行治疗性药物监测(TDM),以评估患者如何代谢药物,并查看剂量是否有效或应更改,将很有用。在治疗过程中,此类信息对于肿瘤科医生而言可能是非常重要的临床工具,使他们能够针对患者改变剂量甚至药物治疗方案,从长远来看可以改善结果。 ud本文介绍了两种不同分析方法的发展在一次测定中对两种药物类型进行定量分析。第一种方法是使用在线SPE-LC-UV,然后将该方法转移到质谱检测器中,以更灵敏地监测药物。在线SPE-LC-MS分析确实降低了检测限,并且是全自动的。整个萃取,分离和检测方法是通过在SPE柱和分析柱之间进行柱切换在线实现的。为了获得人血清中每种目标分析物的最高回收率,评估了两种方法的最佳切换阀类型,提取条件和分离条件。在LC-UV方法中,每种分析物的回收率在86%至117%之间,在LC-MS分析中,大多数分析物的回收率在95%至113%之间。这项研究可能会导致在爱尔兰为使用蒽环类或紫杉烷类或两者治疗的癌症患者引入治疗药物监测。 ud

著录项

  • 作者

    Bermingham Shane;

  • 作者单位
  • 年度 2010
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号